<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30298" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Toxic Shock Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ross</surname>
            <given-names>Adam</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shoff</surname>
            <given-names>Hugh W.</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adam Ross declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hugh Shoff declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30298.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Toxic shock syndrome (TSS) is an acute-onset illness characterized by fever, hypotension, sunburn-like rash, and end-organ damage. TSS was classically associated with high absorbency tampon use in menstruating women until eventually, these were taken off the market. Since that time, it has become important to also consider non-menstrual cases. The incidence of TSS is estimated to be around 0.8 to 3.4 per 100,000 in the United States. This activity reviews the evaluation and treatment of toxic shock syndrome and discusses the role of the interprofessional team in evaluating and treating this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the etiology and pathophysiology of toxic shock syndrome.</p></list-item><list-item><p>Review the history and exam findings of toxic shock syndrome.</p></list-item><list-item><p>Describe the management of toxic shock syndrome.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients with toxic shock syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30298&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30298">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30298.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Toxic shock syndrome (TSS) is an acute-onset illness characterized by fever, hypotension, sunburn-like rash, and end-organ damage. TSS was classically associated with high absorbency tampon use in menstruating women until eventually, these were taken off the market. Since that time, it has become important also to consider non-menstrual cases. The incidence of TSS is estimated to be around 0.8 to 3.4 per 100,000 in the United States.<xref ref-type="bibr" rid="article-30298.r1">[1]</xref><xref ref-type="bibr" rid="article-30298.r2">[2]</xref><xref ref-type="bibr" rid="article-30298.r3">[3]</xref>. Early recognition and antibiotic administration are key to improving patient outcomes and reducing mortality.&#x000a0;</p>
      </sec>
      <sec id="article-30298.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>TSS is most commonly caused by a toxigenic strain of <italic toggle="yes">Staphylococcus aureus</italic> or Group A Strep (<italic toggle="yes">Streptococcus pyogenes</italic>). Other strains of streptococci also produce superantigens, which can lead to TSS. The disease occurs most often in the setting of menstruation despite the discontinuation of high absorbency tampons. However, TSS can also present in non-menstrual settings such as in soft tissue infections, post-surgical infections, burns, retained foreign bodies such as nasal packing, and dialysis catheters. Staphylococcal TSS is typically the result of a localized infection such as an abscess, whereas streptococcal TSS may result from bacteremia, necrotizing fasciitis, or cellulitis.<xref ref-type="bibr" rid="article-30298.r4">[4]</xref></p>
      </sec>
      <sec id="article-30298.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of menstrual and non-menstrual TSS is estimated to be around 0.8 to 3.4 per 100,000 in the United States. The incidence tends to be higher in the winter and is more prevalent in developing countries.&#x000a0;. Infants and the elderly are at highest risk for developing invasive Group A Strep infection, however between 1/5 and 1/3 occur in patients without any predisposing risk factors.&#x000a0;<xref ref-type="bibr" rid="article-30298.r5">[5]</xref>. The skin is the most common source/risk factor for developing severe infection.&#x000a0;<xref ref-type="bibr" rid="article-30298.r6">[6]</xref></p>
      </sec>
      <sec id="article-30298.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>TSS is a toxin-mediated disease that is caused by toxin-producing streptococci or <italic toggle="yes">S. aureus</italic>. These superantigens&#x000a0;bypass the normal pathway for activation of T cells resulting in&#x000a0;over-activation of cytokines and inflammatory cells. This then leads to the presenting signs and symptoms of fever, rash, hypotension, and end-organ failure due to capillary leak. Strep pyogenes (GAS) has other toxins that play a role in necrotizing fasciitis and streptococcal toxic shock syndrome.&#x000a0;<xref ref-type="bibr" rid="article-30298.r5">[5]</xref></p>
      </sec>
      <sec id="article-30298.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>TSS typically presents with rapid onset of fever, rash, and hypotension. It may be preceded by a prodrome of fever and chills with nausea and vomiting as well as nonspecific symptoms such as myalgias, headache, or symptoms of pharyngitis (e.g., a sore throat, painful swallowing), which then progresses to sepsis and organ dysfunction. Risk factors include superabsorbent tampon use, nasal packing, post-operative wound infections, recent influenza infection, as well as immunocompromised states.</p>
        <p>The Center for Disease Control and Prevention (CDC) clinical criteria for TSS includes fever, rash, hypotension, and multisystem organ involvement.&#x000a0;<xref ref-type="bibr" rid="article-30298.r5">[5]</xref> Classically, the rash is a diffuse, blanching, macular erythroderma. Initially it may be a transient macular rash, predominantly on the chest. The rash desquamates one to two weeks later followed by full-thickness peeling. There may be mucosal involvement with strawberry tongue and ulceration of the vaginal mucosa or conjunctival erythema. Patients may exhibit disorientation or altered mental status without focal deficits.&#x000a0;<xref ref-type="bibr" rid="article-30298.r7">[7]</xref></p>
        <p>The CDC defines&#x000a0;Streptococcal Toxic Shock Syndrome as an illness with the following<xref ref-type="bibr" rid="article-30298.r5">[5]</xref><xref ref-type="bibr" rid="article-30298.r7">[7]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Hypotension defined&#x000a0;by a systolic blood pressure less than or equal to 90 mm Hg for adults or less than the fifth percentile by age for children aged less than 16 years.</p>
          </list-item>
          <list-item>
            <p>Multi-Organ Failure characterized by two of the following:
<list list-type="bullet"><list-item><p>Renal impairment: Creatinine greater than or equal to 2 mg/dL (greater than or equal to 177 &#x000b5;mol/L) for adults or greater than or equal to twice the upper limit of normal for age. In patients with preexisting renal disease, a greater than twofold elevation over the baseline level.</p></list-item><list-item><p>Coagulopathy: Platelets less than or equal to 100,000/mm (less than or equal to 100 x 10/L) or disseminated intravascular coagulation, defined by prolonged clotting times, low fibrinogen level, and the presence of fibrin degradation products.</p></list-item><list-item><p>Liver involvement: Alanine aminotransferase, aspartate aminotransferase, or total bilirubin levels greater than or equal to twice the upper limit of normal for the patient's age. In patients with preexisting liver disease, a greater than twofold increase over the baseline level.</p></list-item><list-item><p>Acute respiratory distress syndrome: defined by acute onset of diffuse pulmonary infiltrates and hypoxemia in the absence of cardiac failure or by evidence of diffuse capillary leak manifested by acute onset of generalized edema, or pleural or peritoneal effusions with hypoalbuminemia.</p></list-item><list-item><p>A generalized erythematous macular rash that may desquamate.</p></list-item><list-item><p>Soft-tissue necrosis, including necrotizing fasciitis or myositis, or gangrene.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Laboratory Criteria for Streptococcal Toxic Shock Syndrome:</p>
        <p>Isolation of group A Streptococcus</p>
        <p>They then define the case as Probable if the case meets the criteria in the absence of another etiology and GAS isolated from a non-sterile site.</p>
        <p>The case is defined as confirmed if GAS is isolated from a sterile site (blood, CSF, joint fluid, pleural fluid, or pericardial fluid)&#x000a0;<xref ref-type="bibr" rid="article-30298.r5">[5]</xref><xref ref-type="bibr" rid="article-30298.r7">[7]</xref></p>
      </sec>
      <sec id="article-30298.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There is no specific lab test to identify TSS. A complete blood count (CBC) may show leukocytosis or leukopenia. Bandemia is common. Evaluation of multisystem organ involvement including CBC, CMP, CK, and coagulation studies should be drawn to evaluate for the clinical criteria of TSS.&#x000a0;The CDC defines multisystem organ involvement as vomiting or diarrhea, myalgias, creatine phosphokinase (CPK) greater than two times the upper limit of normal, mucous membrane hyperemia (vaginal, oral, or conjunctival), BUN or creatinine two times the upper limit of normal, bilirubin or AST/ALT two times the upper limit of normal, Platelets less than 100,000, or altered level of consciousness without focal neurologic signs.<xref ref-type="bibr" rid="article-30298.r3">[3]</xref><xref ref-type="bibr" rid="article-30298.r5">[5]</xref><xref ref-type="bibr" rid="article-30298.r3">[3]</xref></p>
        <p>Life-threatening hypocalcemia is prominent throughout the disease and should be repleted accordingly. Anemia, thrombocytopenia, and prolonged coagulation times are also common. Blood cultures and cultures from any suspected source should be obtained. Lumbar puncture should be performed in patients with fever and mental status change to evaluate for meningitis after obtaining coagulation studies.</p>
      </sec>
      <sec id="article-30298.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Patients should receive aggressive intravenous (IV) fluid hydration with crystalloids. Soft tissue infections, especially necrotizing fasciitis should be sought out&#x000a0;and managed. Any source of bacteria such as tampons or nasal packing should immediately be removed. Emergent surgical consultation should be obtained for any wound debridement or surgical cause. This is critical in the early management of toxic shock syndrome.<xref ref-type="bibr" rid="article-30298.r8">[8]</xref><xref ref-type="bibr" rid="article-30298.r9">[9]</xref></p>
        <p>Broad-spectrum antibiotics should be administered for those with an unidentified organism, if possible after blood cultures and cultures from the suspected source have been drawn. For most institutions, this will include vancomycin or linezolid given the high prevalence of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA). Clindamycin should also be administered to suppress toxin production. Studies have shown improved outcomes when Clindamycin is added to antibiotic regimens. <xref ref-type="bibr" rid="article-30298.r5">[5]</xref><xref ref-type="bibr" rid="article-30298.r7">[7]</xref><xref ref-type="bibr" rid="article-30298.r5">[5]</xref>&#x000a0;It should not be given alone as it is bacteriostatic, rather than bactericidal. Given that&#x000a0;it is initially impossible to tell if the infection is polymicrobial, initial therapy should also cover gram-negative organisms.</p>
        <p>Once the organism is identified, and sensitivities have been determined, antibiotics should be optimized and narrowed in the spectrum. Penicillin is the preferred antibiotic for group A strep. For MSSA, clindamycin is recommended, plus flucloxacillin or a beta-lactamase-resistant penicillin such as nafcillin. Current recommendations are to treat for seven to 14 days.</p>
        <p>Vasopressors should be administered for patients with shock refractory to IV fluids. Most current guidelines recommend Norepinephrine as a first option. Intravenous immunoglobulin&#x000a0;(IVIG) is thought to work by neutralizing the activity of the toxins produced and can be considered for shock refractory to fluids and vasopressors. While there are no randomized controlled trials supporting its use, observational trials have shown a reduction in mortality with IVIG compared to patients who only received antibiotics.<xref ref-type="bibr" rid="article-30298.r7">[7]</xref> The optimal dosing is not well established, but high dose at 2 g/kg is acceptable. All patients should be admitted to an intensive care unit. Although a small study from 1984 showed reduced illness severity with steroids, there was no improvement in mortality. Corticosteroids are currently not recommended as adjunctive therapy for TSS.</p>
      </sec>
      <sec id="article-30298.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Scarlet fever</p>
          </list-item>
          <list-item>
            <p>Kawasaki disease</p>
          </list-item>
          <list-item>
            <p>Meningococcemia</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic shock</p>
          </list-item>
          <list-item>
            <p>Necrotizing Fasciitis/Gas gangrene</p>
          </list-item>
          <list-item>
            <p>Drug eruption</p>
          </list-item>
          <list-item>
            <p>Erythema multiforme</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30298.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The case fatality rate of Streptococcal TSS may exceed 50%, particularly with delayed diagnosis; whereas non-streptococcal TSS is less than 3%.&#x000a0;<xref ref-type="bibr" rid="article-30298.r7">[7]</xref><xref ref-type="bibr" rid="article-30298.r5">[5]</xref></p>
        <p>A small study in France showed that non-menstrual Toxic Shock Syndrome had a higher mortality (22%) than that of the menstrual toxic shock syndrome (0%). However, this was a small case series of 55 patients.&#x000a0;<xref ref-type="bibr" rid="article-30298.r10">[10]</xref></p>
      </sec>
      <sec id="article-30298.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Many of the complications from toxic shock syndrome are also part of the diagnostic criteria: end organ damage including renal failure, liver failure, coagulopathy, etc.&#x000a0;In addition to these, glomerulonephritis and rheumatic fever can also occur.&#x000a0;</p>
      </sec>
      <sec id="article-30298.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Almost all of these patients will require admission to the ICU, thus an intensivist should be consulted. Early surgical consultation should also be obtained, particularly given that the most common source is a soft tissue infection or wound, which may require debridement. Infectious Disease physicians&#x000a0;can also assist with the appropriate antimicrobial regimen, particularly given the rarity of this disease.&#x000a0;</p>
      </sec>
      <sec id="article-30298.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Currently it is not recommended to provide prophylaxis for GAS to household contacts despite the increased risk of developing GAS. However, it is important to educate close contacts regarding the symptoms of GAS, and to recommend they seek care immediately should they develop.&#x000a0;<xref ref-type="bibr" rid="article-30298.r11">[11]</xref><xref ref-type="bibr" rid="article-30298.r12">[12]</xref>&#x000a0;Those greater than age 65 are at higher risk of death from GAS, thus it may be reasonable to offer chemoprophylaxis to this population or those at higher risk for GAS.&#x000a0;</p>
        <p>At a minimum, standard precautions should be used in the hospital setting to prevent transmission to patients and staff. The CDC has recommended&#x000a0;for the first 24 hours of effective antibiotics to have the patient in both contact and droplet isolation. <xref ref-type="bibr" rid="article-30298.r5">[5]</xref></p>
      </sec>
      <sec id="article-30298.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>All patients should be admitted to the intensive care until, with more severe cases going to a burn unit. The case fatality rate of Streptococcal TSS may exceed 50% whereas non-streptococcal TSS is less than 3%.&#x000a0; The CDC does not recommend routine screening and chemoprophylaxis of household contacts of patients with invasive Group A Strep (GAS) infections.</p>
        <p>In two large prospective trials, only five cases of invasive GAS occurred amongst almost 2000 household contacts. However, based on risk factors for death from invasive GAS, the CDC states &#x0201c;health care providers may choose to&#x000a0;offer chemoprophylaxis to household members aged 65 years or those at increased risk of sporadic invasive GAS infection&#x0201d;. While there are no large trials with evidence-based regimens, should you choose to&#x000a0;treat household contacts, seven to ten days of oral cephalexin is a reasonable choice. For additional information see the CDC case definitions for Toxic Shock syndrome (other than Streptococcal) and Streptococcal Toxic Shock syndrome.</p>
      </sec>
      <sec id="article-30298.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Toxic shock syndrome is a life-threatening&#x000a0;disorder which carries a very&#x000a0;high mortality. While the mortality rates have decreased over the past 2 decades, they still vary from 1.8-12%. For those patients who are misdiagnosed&#x000a0;or the treatment is delayed, the mortality can exceed 50%. For this reason, healthcare workers should be aware of the disorder and even if they do not manage it, should be able to make a prompt referral. The key in the management of TSS is prevention. The patient needs to be educated on the early signs and symptoms of the disorder and when to seek medical care. In some cases, chemoprophylaxis of household contacts of the patient is recommended. The moment&#x000a0;TSS&#x000a0;is suspected, even during triage to the emergency department, an infectious disease consultant must be called right away. Early surgical consultation in order to identify and manage source control is also critical to improving patient outcomes, as the most common source is a soft tissue infection or wound.&#x000a0;These patients need rapid resuscitation and admission to the ICU. Only with aggressive treatment can the high mortality rates be prevented.<xref ref-type="bibr" rid="article-30298.r13">[13]</xref><xref ref-type="bibr" rid="article-30298.r14">[14]</xref>&#x000a0;(Level V)</p>
      </sec>
      <sec id="article-30298.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30298&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30298">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/toxic-shock-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30298">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30298/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30298">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30298.s17">
        <fig id="article-30298.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Strawberry Tongue. Image of strawberry tongue caused by S<italic toggle="yes">taphylococcus aureus</italic> in a patient with toxic shock syndrome. Public Health Image Library, Public Domain, Centers for Disease Control and Prevention</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Strawberry__Tonue" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30298.s18">
        <title>References</title>
        <ref id="article-30298.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in understanding and managing sepsis.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30345006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sepsis: Early Recognition and Optimized Treatment.</article-title>
            <source>Tuberc Respir Dis (Seoul)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-14</page-range>
            <pub-id pub-id-type="pmid">30302954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vincent</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mongkolpun</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Current management of Gram-negative septic shock.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>600</fpage>
            <page-range>600-605</page-range>
            <pub-id pub-id-type="pmid">30299358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coopersmith</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Deutschman</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lat</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Martin-Loeches</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nunnally</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Hellman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jog</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kesecioglu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rhodes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>1334</fpage>
            <page-range>1334-1356</page-range>
            <pub-id pub-id-type="pmid">29957716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huttner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pugin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Streptococcal toxic shock syndrome in the intensive care unit.</article-title>
            <source>Ann Intensive Care</source>
            <year>2018</year>
            <month>Sep</month>
            <day>17</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <pub-id pub-id-type="pmid">30225523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamagni</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Darenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luca-Harari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Siljander</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Efstratiou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henriques-Normark</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vuopio-Varkila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bouvet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Creti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ekelund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koliou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reinert</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Stathi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strakova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ungureanu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schal&#x000e9;n</surname>
                <given-names>C</given-names>
              </name>
              <collab>Strep-EURO Study Group</collab>
              <name>
                <surname>Jasir</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of severe Streptococcus pyogenes disease in Europe.</article-title>
            <source>J Clin Microbiol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>2359</fpage>
            <page-range>2359-67</page-range>
            <pub-id pub-id-type="pmid">18463210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lappin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Gram-positive toxic shock syndromes.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2009</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>281</fpage>
            <page-range>281-90</page-range>
            <pub-id pub-id-type="pmid">19393958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guirgis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>DeVos</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Updates and controversies in the early management of sepsis and septic shock.</article-title>
            <source>Emerg Med Pract</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">30252228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrier</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Summary of the 2016 International Surviving Sepsis Campaign: A Clinician's Guide.</article-title>
            <source>Crit Care Nurs Clin North Am</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-321</page-range>
            <pub-id pub-id-type="pmid">30098735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Descloux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Perpoint</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vandenesch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mohammedi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Etienne</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-43</page-range>
            <pub-id pub-id-type="pmid">17932694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Rothrock</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Sayler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stefonek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van Beneden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>OS</given-names>
              </name>
              <collab>Active Bacterial Core Surveillance/Emerging Infections Program Network</collab>
            </person-group>
            <article-title>Risk for severe group A streptococcal disease among patients' household contacts.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-7</page-range>
            <pub-id pub-id-type="pmid">12702224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lamagni</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Efstratiou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis?</article-title>
            <source>Lancet Infect Dis</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>494</fpage>
            <page-range>494-500</page-range>
            <pub-id pub-id-type="pmid">16048718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaensbauer</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Birkholz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and Clinical Relevance of Toxic Shock Syndrome in US Children.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>1223</fpage>
            <page-range>1223-1226</page-range>
            <pub-id pub-id-type="pmid">29601458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30298.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Reducing patient mortality, length of stay and readmissions through machine learning-based sepsis prediction in the emergency department, intensive care unit and hospital floor units.</article-title>
            <source>BMJ Open Qual</source>
            <year>2017</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e000158</fpage>
            <pub-id pub-id-type="pmid">29450295</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
